
Exponent Inc
Professional Services
Exponent Inc (EXPO) Stock News
The latest EXPO headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with greater than 50% reduction in death risk, though it did not meet the secondary symptom score endpoint. The safety profile was manageable with no new safety signals observed.
- Benzinga·
MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO
Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO AUSTIN, Texas — May 26, 2026 — MedX Holdings, Inc. (OTC: MEDH ) (soon to be Dazed Inc., pending ticker symbol DAZE), a dynamic brands and acquisition company focused on the emerging hemp, cannabis, and hospitality industries, today announced its financial results for the first quarter ended March 31, 2026. The company is thrilled to report significant year-over-year revenue and gross profit growth, continued profitability, and major traction in its nationwide franchise expansion. Q1 2026 Financial Highlights: Accelerated Growth and Profitability The first quarter of 2026 reflects the power of MedX's strategic focus on high-margin branding, efficient operations, and calculated expansion. Key financial milestones from the Q1 2026 consolidated financial statements include: Solid Revenue Growth: Q1 2026 revenues reached $521,874, representing an impressive 52.7% increase compared to revenues of $341,711 in Q1 2025. Surging Gross Profit: Gross profit for the quarter climbed to $398,990, a 70.6% jump from the $233,793 reported in the same period last year. Sustained Profitability: The company maintained a positive bottom line, reporting a net income of $22,203 for the three months ended March 31, 2026. Expansion on Track: Bringing the "Third Place" to New Cities Following the momentum built in late 2025, ... Full story available on Benzinga.com